1
|
Calderón F, Vidal-Mas J, Burrows J, de la Rosa JC, Jiménez-Díaz MB, Mulet T, Prats S, Solana J, Witty M, Gamo FJ, Fernández E. A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold. ACS Med Chem Lett 2012; 3:373-7. [PMID: 24900481 DOI: 10.1021/ml300008j] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2012] [Accepted: 02/09/2012] [Indexed: 11/30/2022] Open
Abstract
From the 13 533 chemical structures published by GlaxoSmithKline in 2010, we identified 47 quality starting points for lead optimization. One of the most promising hits was the TCMDC-139046, a molecule presenting an indoline core, which is well-known for its anxiolytic properties by interacting with serotonin antagonist receptors 5-HT2. The inhibition of this target will complicate the clinical development of these compounds as antimalarials. Herein, we present the antimalarial profile of this series and our efforts to avoid interaction with this receptor, while maintaining a good antiparasitic potency. By using a double-divergent structure-activity relationship analysis, we have obtained a novel lead compound harboring an indoline core.
Collapse
Affiliation(s)
- Félix Calderón
- Tres Cantos Medicines Development
Campus, DDW, GlaxoSmithKline, Severo Ochoa,
2. 28760 Tres Cantos, Madrid, Spain
| | - Jaume Vidal-Mas
- Tres Cantos Medicines Development
Campus, DDW, GlaxoSmithKline, Severo Ochoa,
2. 28760 Tres Cantos, Madrid, Spain
| | - Jeremy Burrows
- Medicines for Malaria Venture (MMV), 20, route de Pré-Bois-PO Box 1826,
1215 Geneva 15, Switzerland
| | - Juan Carlos de la Rosa
- Tres Cantos Medicines Development
Campus, DDW, GlaxoSmithKline, Severo Ochoa,
2. 28760 Tres Cantos, Madrid, Spain
| | - María Belén Jiménez-Díaz
- Tres Cantos Medicines Development
Campus, DDW, GlaxoSmithKline, Severo Ochoa,
2. 28760 Tres Cantos, Madrid, Spain
| | - Teresa Mulet
- Tres Cantos Medicines Development
Campus, DDW, GlaxoSmithKline, Severo Ochoa,
2. 28760 Tres Cantos, Madrid, Spain
| | - Sara Prats
- Tres Cantos Medicines Development
Campus, DDW, GlaxoSmithKline, Severo Ochoa,
2. 28760 Tres Cantos, Madrid, Spain
| | - Jorge Solana
- Tres Cantos Medicines Development
Campus, DDW, GlaxoSmithKline, Severo Ochoa,
2. 28760 Tres Cantos, Madrid, Spain
| | - Michael Witty
- Medicines for Malaria Venture (MMV), 20, route de Pré-Bois-PO Box 1826,
1215 Geneva 15, Switzerland
| | - Francisco Javier Gamo
- Tres Cantos Medicines Development
Campus, DDW, GlaxoSmithKline, Severo Ochoa,
2. 28760 Tres Cantos, Madrid, Spain
| | - Esther Fernández
- Tres Cantos Medicines Development
Campus, DDW, GlaxoSmithKline, Severo Ochoa,
2. 28760 Tres Cantos, Madrid, Spain
| |
Collapse
|
2
|
Rueda L, Castellote I, Castro-Pichel J, Chaparro MJ, de la Rosa JC, Garcia-Perez A, Gordo M, Jimenez-Diaz MB, Kessler A, Macdonald SJ, Martinez MS, Sanz LM, Gamo FJ, Fernandez E. Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS). ACS Med Chem Lett 2011; 2:840-4. [PMID: 24900273 DOI: 10.1021/ml2001517] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2011] [Accepted: 08/29/2011] [Indexed: 11/28/2022] Open
Abstract
Rapid triaging of three series of related hits selected from the Tres Cantos Anti-Malarial Set (TCAMS) are described. A triazolopyrimidine series was deprioritized due to delayed inhibition of parasite growth. A lactic acid series has derivatives with IC50 < 500 nM in a standard Plasmodium falciparum in vitro whole cell assay (Pf assay) but shows half-lives of < 30 min in both human and murine microsomes. Compound 19, from a series of cyclopropyl carboxamides, is a highly potent in vitro inhibitor of P. falciparum (IC50 = 3 nM) and has an oral bioavailability of 55% in CD-1 mice and an ED90 of 20 mg/kg after oral dosing in a nonmyelo-depleted P. falciparum murine model.
Collapse
Affiliation(s)
- Lourdes Rueda
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Isabel Castellote
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Julia Castro-Pichel
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Maria J. Chaparro
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Juan Carlos de la Rosa
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Adolfo Garcia-Perez
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Mariola Gordo
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Maria Belen Jimenez-Diaz
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Albane Kessler
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Simon J.F. Macdonald
- Medicines for Malaria Venture, ICC, Route de Pre-Bois, PO Box 1826, 1215 Geneva 15, Switzerland
| | - Maria Santos Martinez
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Laura M. Sanz
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Francisco Javier Gamo
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| | - Esther Fernandez
- Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW), GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Spain
| |
Collapse
|